Total Therapy 3 (2003-33) in Gene Expression Profiling-Defined Low-Risk Multiple Myeloma Confirmed in Subsequent Trial 2006-66 with Bortezemib, Lenalidomide and Dexamethasone (VRD) Maintenance
Van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy Jr JD, Hoering A, Crowley J, Barlogie B. Total Therapy 3 (2003-33) in Gene Expression Profiling-Defined Low-Risk Multiple Myeloma Confirmed in Subsequent Trial 2006-66 with Bortezemib, Lenalidomide and Dexamethasone (VRD) Maintenance. Blood. 2010.